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PreviewsTLR Ignores Methylated RNA?
CpG methylation of DNA silences TLR9-mediated in-
nate immune recognition. In this issue of Immunity,
Kariko et al. (2005) suggest that the innate immune
recognition of RNA by TLR3, TLR7, or TLR8 is in fact
controlled by modification of nucleotides, including
methylation.
Nucleic acids such as DNA and RNA are essential ele-
ments of all living organisms. Evidence that has accu-
mulated over the past few decades suggests that nucleic
acids are normally sequestered but can be released from
pathogens or damaged host cells and are then recog-
nized by the innate immune system (Isaacs et al., 1963;
Tokunaga et al., 1984). The recent discovery of Toll-like
receptors (TLRs) and the extensive studies that fol-
lowed have revealed that certain TLRs recognize nu-
cleic acids derived from infectious organisms or dam-
aged host cells, resulting in modulation of immune
responses (Figure 1) (Akira and Takeda, 2004).
Although certain RNAs such as double-stranded (ds)
RNA have long been known to be immunologically
active, it is only recently that TLR-mediated recognition
of RNA has been described. TLR3 recognizes dsRNA
derived from virus or host mRNA (Alexopoulou et al.,
2001; Kariko et al., 2004). TLR7 and TLR8 have recently
been shown to recognize viral or synthetic single-
stranded (ss) RNA (Heil et al., 2004; Diebold et al., 2004)
or double-stranded, short-interfering RNA (siRNA) (Hor-
nung et al., 2005). These findings have facilitated our
understanding of innate immune recognition of RNA
but have also left unsolved issues. In particular, we do
not know exactly why a variety of self-RNA species,
abundant in the host cells, are not continuously stimu-
lating our immune system. Exactly what element(s) of
RNA do TLR3, TLR7, or TLR8 recognize? In other
words, are there any specific rules with respect to li-
gand structure or chemistry for elicitation of responses
from these TLRs?
There are some clues in recent reports. An initial
study indicated that the presence of GU- or U-rich se-
quences in virus-derived ssRNA might explain some of
the differences between stimulatory and inert ssRNA
(Diebold et al., 2004; Heil et al., 2004). Although this
idea was attractive, a recent report showed that high
GU content was not critical in the case of TLR7-medi-
ated recognition of siRNA (Hornung et al., 2005). A
plausible explanation was consequently offered: that
normally abundant host ssRNAs are usually seques-
tered within intact cell membranes or immediately de-
graded by abundant RNases, thereby limiting their ac-
cessibility to the endosomal compartments in which
TLR3, TLR7, or TLR8 reside. This spatial safety mecha-
nism to prevent aberrant innate activation by RNA isbroken by certain exceptional conditions such as a
virus infection or tissue damage (Crozat and Beutler,
2004).
Other reports offered an alternative hypothesis,
namely that there may still be a specific element in the
RNA responsible for its immunomodulatory activity.
Messenger RNAs derived from bacteria without poly(A)
tails, but not from vertebrate mRNA with such se-
quences, displayed immunostimulatory activity on hu-
man myeloid dendritic cells (Koski et al., 2004). This
could explain why bacterial, but not host, RNA is stimu-
latory. Similarly, unmethylated CpG motifs, more fre-
quently observed in bacterial and certain viral DNA,
may be mirrored in mRNA expressed by such patho-
gens. In fact, ssRNA with unmethylated CpG motifs
was immunostimulatory, and its activity was abrogated
if the 5# position of C was methylated, similar to that
of CpG DNA, although the stimulatory effects were not
simply mediated by TLR7 or TLR8 (Sugiyama et al.,
2005). Interestingly, not only 5#-C methylation in CG di-
nucleotides but also 2#-O methylation of any nucleo-
tides in ssRNA abrogated the immunostimulatory ef-
fects (Sugiyama et al., 2005). Many other modifications
are currently known to be present in vertebrate RNAs as
compared to bacterial RNAs, suggesting that these ver-
tebrate-specific modifications, including methylation
(see the web site http://medlib.med.utah.edu/RNAmods/),
may be key to limiting their activity.
In this issue of Immunity, Kariko et al. (2005) extens-
ively examined the effects of major RNA modifications
on TLR-mediated innate immune activation and came
up with surprising but intriguing results (Kariko et al.,
2005). First, the authors observed that among natural
RNA, lipofection of bacterial, but not mammalian, RNA
(with an exception of mitochondrial RNA) activated hu-
man myeloid dendritic cells (DCs) to secrete TNFα. As
noted above, mammalian RNA should have been active
if the access of RNA to TLR-expressing endosomes is
the safety mechanism keeping abundant self-RNA from
mediating immune stimulation. Instead, these investi-
gators demonstrated that modification of RNA, includ-
ing methylation, is the major controller of RNA immuno-
modulatory activity. Synthetic ssRNAs of different
sequences and lengths could activate TLR3-, TLR7-,
and TLR8-expressing cells to secrete IL-8, an activity
that was severely impaired when modified nucleosides
such as N6-methyaladanosine, 5-methylcytidine, 2-thi-
ouridine, or pseudouridine were introduced into the
RNA. Because these modifications are observed more
frequently in mammalian RNA than in RNA from bacte-
ria, they may explain why synthetic unmodified RNA
corresponding to host RNA sequences is immunostim-
ulatory but natural host RNA is not. Overall, these new
data strongly suggest that TLR3, TLR7, and TLR8 re-
cognize “unmethylated RNA,” similar to TLR9 rec-
ognition of unmethylated CpG motifs in DNA.
This new study also extended our understanding of
nucleic acid stimulation of TLRs in other ways. TLR3-
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112mediated RNA recognition was not altered by the pres- w
ence of pseudouridine, which is known to stabilize RNA M
duplex formation. Conversely, modification of stimula- v
tory RNA with N6-methyaladanosine, which destabi- a
lizes RNA duplexes, abrogates TLR3-mediated immune i
activations. These results strongly support previous
findings that TLR3 recognizes the double-stranded por-
tion of RNA. Furthermore, N6-methyaladanosine, found K
in many viral RNAs, also diminishes TLR7- and TLR8- 1
Jmediated RNA recognition, implying that such mod-
2ification is ideal for viral evasion of TLR-mediated
Rimmune responses, as the authors discuss. Finally,
Ounmodified, but not modified, RNA potently activated
3in vitro generated or freshly isolated human DCs, lead-
Sing to production of IL-12 and IFNα as well as the en-
Ohanced expression of costimulatory molecules. These
Jdata will help guide development of therapeutic appli-
cations of RNA, because avoiding modification may
enhance the potency of immunotherapy involving RNA-
based vaccines or the use of RNA as an adjuvant. Con- S
versely, appropriate nucleotide modifications could re-
sult in more efficient RNAi by dsRNA, including siRNA. A
The new findings of Kariko et al. (2005) lead to two A
major conclusions about TLR-mediated RNA recogni- N
tion. The first is that TLR3, TLR7, and TLR8 can recog- C
nize the same naturally isolated or synthetic RNA. The 6
second is that the elements involved in TLR-mediated D
RNA responses are controlled by modifications such C
as methylation (Figure 1). Further confirmation and/or H
exploration of their findings in other experimental sys- A
1tems, such as in vivo studies with mutant mice altered
in TLR and TLR signaling pathway, is still required to H
Sflesh out these new findings. It will be of interest to
Flearn whether such modifications of RNA have an im-
pact on TLR-independent innate recognition of RNA IFigure 1. Innate Immune Recognition of Nu-
cleic Acids
Nucleic acids (DNA or RNA) are normally se-
questered but can be released from patho-
gens or damaged host cells. TLR-dependent
and independent recognition of RNA as well
as DNA have been described. TLR9 recog-
nizes unmethylated CpG motifs in DNA.
Methylation of 5’C (m5C) of CpG DNA abro-
gates TLR9-mediated recognition and acti-
vation. In this issue of Immunity, Kariko et
al. (2005) demonstrated that TLR3, TLR7, and
TLR8 can recognize both single- and double-
stranded RNA. Such RNA-induced immune
activation is influenced by nucleotide modifi-
cations (e.g. 5’-methylcytidine [m5C], N6-
methyladenosine [m6A], and pseudouridine
[ψ]). Currently known innate recognitions are
shown in this graphic, including receptors,
adaptors, signal transductions, and tran-
scriptions. An unknown but predicted mole-
cule and a pathway are shown as a question
mark or a dotted line, respectively.ithin cells through molecules such as RIG-I and
DA-5 and, of course, what the physiological rele-
ance of their findings is to infectious diseases as well
s to immunological disorders associated with RNA-
nduced immunomodulation.
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